VIVID-1 trial
Mirikizumab Shows Superior Histologic Response in Crohn’s Disease Compared to Ustekinumab
Mirikizumab, Ustekinumab, Crohn’s Disease, Histologic Response, VIVID-1 Trial, Inflammatory Bowel Disease
Actionable Insights Powered by AI
Mirikizumab, Ustekinumab, Crohn’s Disease, Histologic Response, VIVID-1 Trial, Inflammatory Bowel Disease